• New data generated at Scripps Research Institute in the US shows that Starpharma’s antiviral nasal spray active (SPL7013) is virucidal, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19
  • Potent antiviral activity of SPL7013 against SARS-CoV-2 was evident when used either before or after exposure of cells to the virus meaning that the nasal spray could be used before or after exposure to the virus
  • Starpharma is rapidly advancing development, regulatory, manufacturing and commercialisation activities and leveraging its extensive technical data set and approved status of SPL7013 to expedite approval with product now expected to be ready for market 1H CY2021

MELBOURNE, Australia--(BUSINESS WIRE)--Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.

The latest results confirm that when SPL7013 is applied at the concentration of the SPL7013 COVID-19 nasal spray, it has potent virucidal activity, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19.

These data expand on the previously announced (see previous ASX announcement - 25 August 2020) data showing that SPL7013 has potent antiviral activity and inhibits infection of host cells by SARS‑CoV-2 when the compound is applied to the cells either before or after exposure to the virus. Earlier testing also showed that SPL7013 has a very favourable and high selectivity index1 (up to ~2200), indicating potent antiviral efficacy with minimal cellular toxicity. The high selectivity index of SPL7013 compares very favourably with the selectivity index against SARS-CoV-2 reported in the literature of 279 for remdesivir and 55 for hydroxychloroquine.2,3

Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to be working with Professor Gallay to expedite the development of this important product. These latest data show that at clinically relevant concentrations (at the concentration of the SPL7013 COVID‑19 nasal spray), SPL7013 inactivates more than 99.9% of SARS-CoV-2, which represents a compelling feature for the product. This potent virucidal action is consistent with the activity seen for SPL7013 in other viruses, including HIV and HSV.”

Professor Gallay commented: “We have been working with Starpharma for a number of months now and are impressed with the antiviral data generated in our lab for SPL7013 against SARS-CoV-2. It is particularly exciting to see a product show such a potent and clear virucidal effect against this highly infectious virus, and for its antiviral activity to be present when SPL7013 is added either before or after exposure of cells to the virus.”

Dr Fairley added “Starpharma’s COVID-19 nasal spray has potential to be an important near-term preventative product, and given it is based on an already marketed active, its path to market is both faster and less complex than a completely new product. Another attractive feature of Starpharma’s SPL7013 COVID-19 nasal spray is that it is entirely complementary to other prevention measures such as PPE and vaccines. It also has special relevance where social distancing is not possible such as crowded environments and certain workplaces. The importance of having multiple preventative product strategies has been highlighted by the recent challenges with some vaccine trials. Starpharma’s topical antiviral nasal spray could play a role both prior to vaccines being available, and complementary to vaccines once available to further reduce risk.”

Starpharma is expediting the development of the SPL7013 nasal spray and has already completed reformulation, pilot product manufacture, selection of device and packaging components, identification of manufacturer and compiled regulatory documentation in preparation for submission (see previous ASX announcement - 25 August 2020). The company has also commenced commercial discussions across a range of distribution channels and customer groups (e.g. B2B, online platforms) and expects that the product will be ready for market in 1H CY2021.

SPL7013 Mechanism of antiviral action

SPL7013 inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins. As for other viruses inhibited by SPL7013, SARS-CoV-2 infects human cells by using the characteristic viral surface proteins, or “spikes”, to attach to receptor proteins on the surface of human cells and SPL7013 blocks this interaction.

About SPL7013 COVID-19 nasal spray

SPL7013 is a broad-spectrum antiviral with potent SARS-CoV-2 activity and is also the active in VivaGel® marketed products approved in UK, Europe, Asia, Canada, Australia, and New Zealand. SPL7013 acts early in the viral replication cycle and has virucidal activity against SARS-CoV-2 with antiviral activity evident when used either before or after exposure of cells to the virus. SPL7013 inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins. SPL7013 has broad spectrum antiviral and virucidal effects, with activity demonstrated against a range of viruses, including HIV, herpes simplex virus (HSV), human papillomavirus (HPV), adenovirus, H1N1 influenza virus, hepatitis B virus (HBV) and Zika virus.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Disclosure This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

1 Selectivity index is a ratio of antiviral activity to cellular toxicity. The higher the selectivity index, the theoretically safer and more effective a compound would be in humans. 2 Pizzorno, A., et al., 2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 104878. Advance online publication. https://doi.org/10.1016/j.antiviral.2020.104878 3 Liu, J., et al., 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 6(16). https://doi.org/10.1038/s41421-020-0156-0

Contacts

Media: WE Communications Rebecca Wilson Mob: +61 417 382 391 rwilson@we-worldwide.com

Arthur Chan +61 2 9237 2805 arthurc@we-worldwide.com

Starpharma Holdings Limited Dr Jackie Fairley, Chief Executive Officer Nigel Baade, CFO and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067